Connecticut Innovations, the state’s quasi-public venture capital arm, said it has invested $300,000 in IsoPlexis, a Branford company developing a research tool for cancer drug developers.
New York’s Spring Mountain Capital also invested an undisclosed sum in IsoPlexis.
IsoPlexis will use the capital infusion to finalize a beta version of its product, a micro-device designed to help drug developers analyze drug reactions at the cellular level. The capital will also help support additional hospital and clinical case studies, CI said.
IsoPlexis was founded in 2012 by Yale researchers.
